by Agathe Masson | Dec 17, 2024 | NCD Case Studies, NCD Partnerships, News
Following the agreement on a new licensing model between the Medicines Patent Pool (MPP) & Novartis in collaboration with the ATOM Coalition, generic, quality-assured nilotinib is now available on NCDconnect! This initiative is crucial in making lifesaving...
by Agathe Masson | Dec 9, 2024 | Access to Care, NCD Solutions, News
Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions of people worldwide. Between 2010 and 2050, an estimated 14 million babies will be affected globally, with the vast majority born in low- and middle-income countries (LMICs). This staggering...
by Agathe Masson | Nov 19, 2024 | Healthcare Systems, NCD Policy, News
“Localisation.” It’s a term we’ve heard frequently in recent years, but not without its critics—and perhaps rightly so. Many argue that “localisation” doesn’t fully capture the essence of legitimising communities to lead their own health solutions, often implying a...
by Agathe Masson | Feb 5, 2024 | Access to Care, NCD Partnerships, News
IDA Foundation and the Access to Oncology Medicines (ATOM) Coalition are happy to announce their strategic partnership. Following World Cancer Day’s theme ‘Close the Care Gap’, this collaboration marks a significant step toward addressing the challenges of...
by Callie Weber | Jan 8, 2024 | Access to Care, NCD Policy, News
Counterfeit and substandard medicine trafficking is one of the world’s fastest-growing and highest-value criminal enterprises. Analysts estimate the global counterfeit market to be worth between US$200 and $432 billion. Since the issue first came to light in a 2003...
